Accueil   Diary - News   All news ELSALYS BIOTECH acquires from JAZZ PHARMACEUTICALS the worldwide rights of LEUKOTAC®

ELSALYS BIOTECH acquires from JAZZ PHARMACEUTICALS the worldwide rights of LEUKOTAC®

LEUKOTAC® is an immunotherapy antibody with clinical benefits in steroid-resistant acute Graft-versus-Host Disease

 

 

  • In a recent clinical study, it has shown a - favorable risk/benefit profile, supporting the experience already obtained with LEUKOTAC® in nearly 1,200 patients with acute graft-versus-host disease (aGvHD).

 

  • Developed to date by JAZZ PHARMACEUTICALS, LEUKOTAC® has received an orphan designation in Europe and the United States.

 

  • ELSALYS BIOTECH has initiated discussion with the European health authorities (EMA) and will engage in regulatory interactions with the FDA in 2018.

 

Lyon, FRANCE, October 12, 2017, ELSALYS BIOTECH, a new player in immuno-oncology, has acquired from JAZZ PHARMACEUTICALS the development and commercialization rights of LEUKOTAC® (inolimomab), a monoclonal antibody that has recently demonstrated its clinical superiority in the treatment of Steroid-Resistant acute Graft-versus-Host Disease (steroid-resistant aGvHD), an orphan disease with very poor prognosis.

 

 

Read the press release

 

 

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree